NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides, Inc. has secured approximately $6 million in new funding through a registered direct offering and concurrent private placement, providing essential capital to advance its pipeline of broad-spectrum antiviral nanomedicines. The clinical-stage company entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock at $1.68 per share, generating expected gross proceeds of $6 million before expenses.
In a concurrent private placement, the company will issue Series A and Series B warrants, each providing the right to purchase up to 3,571,429 additional shares. The Series A warrants carry an exercise price of $1.75 per share and will be exercisable six months after issuance, expiring in two years. The Series B warrants feature a $2.00 exercise price, becoming exercisable after six months and expiring in 5.5 years. The offering is expected to close on or about November 12, 2025, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as sole placement agent.
The capital infusion comes at a critical time for NanoViricides as the company advances its lead drug candidate NV-387 toward Phase II human clinical trials. NV-387 represents a broad-spectrum antiviral drug being developed for multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, as well as MPOX/Smallpox infections. The company's other advanced candidate, NV-HHV-1, targets shingles treatment, positioning NanoViricides to address significant unmet medical needs across multiple viral disease categories.
Proceeds from the financing will be allocated to working capital and general corporate purposes, supporting the company's ongoing research and development efforts. The funding demonstrates continued investor confidence in NanoViricides' platform technology, which is based on intellectual property licensed from TheraCour Pharma, Inc. The company holds exclusive, sub-licensable field licenses for developing drugs against numerous viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue viruses, and Ebola/Marburg viruses, among others.
The financing announcement follows the company's strategic focus on advancing its nanoviricide technology platform, which creates special purpose nanomaterials for antiviral therapy. Additional information about the company's development programs and technology can be found at https://www.nanoviricides.com. The company has emphasized that the typical drug development path requires substantial capital and extended timelines, noting that successful laboratory results do not guarantee successful clinical trials or commercial products.
This funding round represents a significant milestone for NanoViricides as it works to advance multiple antiviral candidates through clinical development. The company's broad pipeline addresses numerous viral threats that continue to pose significant global health challenges, from common respiratory infections to more severe viral diseases. The successful capital raise positions the company to continue its research efforts while navigating the complex regulatory pathway required for antiviral drug development.